Table 2.
Characteristics of patients with respect to prior daptomycin exposure
| Prior Daptomycin Exposure | No Daptomycin Exposure | P value* | |
|---|---|---|---|
| Number of Isolates |
15 (60%) |
10 (40%) |
-- |
| Age |
52.5 |
51.8 |
-- |
| Sex – no (%) |
|
|
|
| -Female |
8/15 (53%) |
6/10 (60%) |
0.742 |
| Isolate |
|
|
|
| -E. faecium |
14 (93%) |
4 (67%) |
0.115 |
| -E. faecalis |
0 (0%) |
2 (33%) |
0.019 |
| -Species Not Identified |
1 (7%) |
0 (0%) |
-- |
| -Isolate Not Availablea |
0 |
4 |
-- |
| Source |
|
|
|
| -Bloodb |
7 (47%) |
2 (20%) |
0.174 |
| -Urineb |
5 (33%) |
7 (70%) |
0.072 |
| -Peritoneal Fluid |
2 (13%) |
1 (10%) |
0.802 |
| -Wound |
2 (13%) |
0 (0%) |
0.229 |
| -Colonizationc |
4 (27%) |
4 (40%) |
0.484 |
| Past Medical History |
|
|
|
| -Diabetes |
6 (40%) |
6 (60%) |
0.327 |
| -ESRD/Dialysis |
2 (13%) |
1 (10%) |
0.802 |
| -Cancer/Chemotherapyd |
8 (53%) |
4 (40%) |
0.513 |
| -History of Transplant |
2 (13%) |
0 (0%) |
0.229 |
| -CVDe |
3 (20%) |
4 (40%) |
0.275 |
| -Lung Diseasef |
2 (13%) |
2 (20%) |
0.656 |
| GI or Intra-abdominal Processg |
12 (80%) |
7 (70%) |
0.566 |
| Immunosuppressionh |
14 (93%) |
7 (70%) |
0.119 |
| Deathi | 8 (53%) | 2 (20%) | 0.096 |
Note:
* - All P values were calculated with the use of the chi-square test.
a – Four isolates were not available for species identification.
b – One patient with DNSE and prior daptomycin exposure had DNSE isolated from both blood and urine.
c – All colonizing isolates were obtained from urine of patients without symptoms and/or negative urinalysis.
d – includes all patients with acute lymphoblastic leukemia, acute myelogenous leukemia, myelodysplastic syndrome, bone marrow transplant, stem cell transplant, solid organ tumor, and those undergoing chemotherapy.
e – includes all patients with coronary artery disease, congestive heart failure, cerebro-vascular accident, peripheral vascular disease, and valvular heart disease.
f – includes all patients with chronic obstructive pulmonary disease and pulmonary hypertension.
g – includes all patients with Clostridium difficile infection, graft-versus-host-disease of the gut, neutropenic enterocolitis/perforation, traumatic bowel perforation, bowel ischemia, bacterial peritonitis, ascending cholangitis, gastroparesis, pyelonephritis and/or kidney abscess, or other gastrointestinal surgery with complications.
h – includes all patients with any cancer or undergoing chemotherapy, diabetes mellitus, ESRD/HD, organ transplant.
i – Hospital and/or thirty-day mortality from any cause.